Equities Analysts Set Expectations for AGIO Q3 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities researchers at Zacks Research decreased their Q3 2025 EPS estimates for shares of Agios Pharmaceuticals in a research report issued to clients and investors on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.80) per share for the quarter, down from their prior estimate of ($1.79). The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($4.87) per share. Zacks Research also issued estimates for Agios Pharmaceuticals' Q4 2025 earnings at ($1.79) EPS, FY2025 earnings at ($6.99) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.57) EPS, Q3 2026 earnings at ($1.52) EPS and FY2026 earnings at ($5.95) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts' consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million for the quarter, compared to analysts' expectations of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm's quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.51) EPS.

A number of other equities analysts also recently issued reports on AGIO. Leerink Partners downgraded shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, October 16th. Raymond James reiterated an "outperform" rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has a consensus rating of "Hold" and an average price target of $52.00.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock traded up $0.01 during trading hours on Friday, reaching $45.09. 426,071 shares of the stock were exchanged, compared to its average volume of 694,641. The firm's 50 day moving average is $44.64 and its 200 day moving average is $41.46. The stock has a market cap of $2.56 billion, a P/E ratio of -7.13 and a beta of 0.75. Agios Pharmaceuticals has a 52-week low of $19.80 and a 52-week high of $53.28.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company's stock, valued at $988,346.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company's stock, valued at $988,346.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brian Goff sold 11,091 shares of the firm's stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth approximately $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 363 shares during the last quarter. CWM LLC boosted its position in shares of Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, North Star Asset Management Inc. acquired a new position in Agios Pharmaceuticals during the second quarter valued at approximately $216,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.